Invasion and metastasis

Cancer and Metastasis Reviews

Volumn 15, Issue 1, 1996, Pages 77-89

  Boyd, Douglas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

collagenase; protease; signal transduction; transcription; urokinase

Indexed keywords

COLLAGENASE; GROWTH FACTOR; HYDROLASE; PROTEINASE; STROMELYSIN; UROKINASE;

GENE EXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 0029948736     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00049488     Document Type: Review

References (95)

1. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191-217, 1987
2. Hirota J, Yoneda K, Osaki T: Basement membrane type IV collagen in oral squamous tell carcinoma. Head and Neck 12: 400-405, 1990
3. Robbins KC, Summaria L, Hsieh B, Shah R: The peptide chains of human plasmin. J Biol Chem 242: 2333-2342, 1967
4. Liotta L, Goldfarb R, Brundage R, Siegel G Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636, 1981
5. Salo T, Liotta L, Keski-Oja J, Turpcenniemi-Hujanen T, Tryggvason K: Secretion of basement collagen degrading enzyme and plasminogen activator by transformed cells-Role in metastasis. Int J Cancer 30: 669-673, 1982
6. Ossowski L, Reich F: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983
7. Yu U, Schultz R: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623-7633, 1991
8. Achbarou A, Kaiser S, Tremblay G Ste-Marie L, Brodt P, Goltzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994
9. Sappino A, Belin D, Huarte J, Hirschel-Scholz S, Saurat J, Vassalli J: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079, 1991
10. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS: Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatology 98: 351-358, 1992
11. Clayman G, Wang SW, Nicolson GL, El-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd D: Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int J Cancer 54: 73-80, 1993
12. Bernhard EJ, Muschel RJ, Hughes EN: Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50: 3872-3877, 1990
13. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91: 4293-4297, 1994
14. Wilhelm SM, Collier IE, Manner BL, Eisen AZ, Grant G, Goldberg G: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. Degrades type IV collagen. Activation leads to removal of 73 amino acids. Contains zinc-binding domain and fibronectin domain. J Biol Chem 264: 17213-17221, 1989
15. Goldberg G, Strongin A, Collier IE, Genrich T, Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583-4591, 1992
16. Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802-5807, 1993
17. Bernhard EJ, Hagner B, Wong C, Lubenski I, Muschel RJ: The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer 60: 718-724, 1995
18. Pyke C, Ralkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenase in human skin cancers by in situ hybridization. Cancer Res 52: 1336-1341, 1992
19. Juarez C, Clayman G, Nakajima M, Tanabe K, Saya H, Nicolson GL, Boyd D: Role and regulation of 92 kDa type IV collagenase (MMP-9) in invasive squamous cell carcinoma of the oral cavity. Int J Cancer 54: 73-80, 1993
20. Garbisa S, Scagliotti G, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG, Liotta L: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548-4549, 1992
21. Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg G: Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 5: 75-83, 1990
22. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629-3633, 1995
23. Huhtala P, Chow L, Tryggvason K: Structure of the human type IV collagenase gene. J Biol Chem 265: 11077-11082, 1990
24. Collier IE, Bruns GAP, Goldberg GI, Gerhard DS: On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics 9: 429-434, 1991
25. Overall CM, Wrana JL, Sodek J: Transcriptional and posttranscriptional regulation of 72 kDa gelatinase/type IV collagenase by transforming growth factor-beta in human fibroblasts. J Biol Chem 266: 14064-14071, 1991
26. Okada A, Belloco J, Rouyer N, Chenard M, Rio M, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92: 2730-2734, 1995
27. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994
28. Matrisian LM: The matrix-degrading metalloproteinases. BioEssays 14: 445-463, 1992
29. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 48: 550-556, 1991
30. Gray ST, Wilkins RJ, Yun K: Interstitial collagenase gene expression in oral squamous cell carcinoma. American Journal of Pathology 141: 301-306, 1992
31. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio M, Eber M, Methlin G et al.: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53: 165-169, 1993
32. Bejarano PA, Noekken ME, Suzuki K, Hudson BG, Nagase H: Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin). Biochem J 256: 413-419, 1988
33. Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P: Detection of mRNAS encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by HI situ hybridization. Invasion Metastasis 11: 76-83, 1991
34. Polette M, Clavel C, Birembaut P, De Clerck YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathology Research and Practice 189: 1052-1057, 1993
35. Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan E, Boyd D: Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombosis and Haemostasis 68: 662-666, 1992
36. Henderson BR, Tansey WP, Phillips SM, Ranshaw IA, Kefford RE: Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489-2496, 1992
37. Nanbu R, Menoud P, Nagamine Y: Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 14: 4920-4928, 1995
38. Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405, 1993
39. Huhtala P, Tuuttila A, Chow L, Lohi J, Keski-Oja J, Tryggvason K: Complete structure of the human gene for 92-kDa type IV collagenase. J Biol Chem 266: 16485-16490, 1991
40. Lyons J, Birkedal-Hansen H: Interleukin-1b and transforming growth factor/EGF induce expression of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes. J Biol Chem 268: 19143-19151, 1993
41. Sato H, Kita M, Seiki M: v-src activates the expression of 92-kDa type IV collagenase through the AP-1 site and the GT Box homologous to retinoblastoma control elements. J Biol Chem 268: 23460-23468, 1993
42. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nucl Acids Res 13: 2759-2771, 1985
43. Verde P, Boast S, Franze A, Robbiati F, Blasi F: An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucl Acids Res 16: 10699-10715, 1988
44. Von der Ahe D, Pearson D, Nagamine Y: Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role of protein phosphorylation. Nucleic Acids Research 18: 1991-1999, 1990
45. Menoud P, Matthies R, Hofsteenge J, Nagamine Y: Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine uPA gene. Nucleic Acids Research 21: 1845-1852, 1993
46. Nerlov C, Rorth P, Blasi F, Johnsen M: Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6: 1583-1593, 1991
47. Verde P, Stoppeth MP, Galeffi P, Di Nocera P, Blasi F: Identification and primary sequence of an unspliced human urokinase poly (A+) RNA. Proc Nat Acacl Sci USA 81: 4727-4731, 1984
48. Kasai S, Arimura H, Nishida M, Suyama T: Primary structure of single-chain pro-urokinase. J Biol Chem 260: 12382-12389, 1985
49. Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F: Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J 5: 855-861, 1986
50. Rossi P, Grimaldi P, Blasi F, Geremia R, Verde P: Follicle-stimulating hormone and cyclic AMP induce transcription from the human urokinase promoter in primary cultures of mouse Sertoli cells. Molecular Endocrinology 4: 940-946, 1990
51. Rorth P, Nerlov C, Blasi F, Johnsen M: Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbolester. Nucleic Acids Research 128: 5009-5017, 1990
52. Nerlov C, De Cesare D, Pergola F, Carracciolo A, Blasi F, Johnsen M, Verde P: A regulatory element that mediates co-operation between a PEA3-AP-1 element and AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11: 4573-4582, 1992
53. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, BAeuerle A, Blasi F: A novel complex between the p65 subunit ot NF-kB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11: 205-213, 1992
54. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P: Heterodimerization of c-jun with ATF-2 and c-fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 11: 365-376, 1995
55. Kolesnick R, Golde DW: The spingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77: 325-328, 1994
56. Karin M: Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr Opin Cell Biol 6: 415-424, 1994
57. Pepper MS, matsumoto K, Nakamura T, Orei L, Montesano R: Hepatocyte growth factor increases urokinasetype plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267: 20493-20496, 1992
58. Stacey DW, Roudebush M, Day R, Mosser SD, Gibbs JB, Feig LA: Dominant inhibitory ras mutants demonstrate the requirement for ras activity in the action of tyrosine kinase oncogenes. Oncogene 6: 2297-2304, 1991
59. Graziani A, Gramaglia D, Zonca P, Comoglio PM: Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 268: 9165-9168, 1993
60. Sasaoka T, Langlois WJ, Leitner JW, Draznin B, Olefsky JM: The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 268: 32621-32625, 1494
61. Kuzumaki N, Ggiso Y, Oda A, Fujita U, Suzuki H, Sato C, Mullauer I.: Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 313 cells. Mol Cell Biol 9: 2258-2263, 1989
62. Huang W, Alessandrini A, Crews CM, Erikson RL: Raf-1 forms a stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proc Natl Acad Sci USA 90: 10947-10951, 1993
63. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by raf-1 and MEKK. Science 266: 1719-1722, 1994
64. Bruder JT, Heidecker G, Rapp UR: Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes and Development 6: 545-556, 1992
65. Kyriakis JM, App H, Zhang X, Banerjee P, Brautigan DL, Rapp UR, Avruch J: Raf-1 activates MAP kinase-kinase. Nature 358: 417-420, 1992
66. Crews CM, Alessandrini A, Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258: 478-480, 1992
67. Gille H, Sharrocks AD, Shaw PE: Phosphorylation of transcription factor p62tcf by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414-417, 1992
68. Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE, Stabel S: Activation of the c-raf protein kinase by protein kinase C phosphorylation. Oncogene 7: 2259-2262, 1992
69. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M: Identification of a dual specificity kinase that activates the Jun Kinases and p38-Mpk2. Science 268: 286-290, 1995
70. Galang CK, Der CJ, Hauser CA: Oncogenic ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. Oncogene 9: 2913-2921, 1994
71. Deng T, Karin M: c-Fos transcriptional activity stimulated by H-ras-activated protein kinase distinct from JNK and ERK. Nature 371: 171-175, 1995
72. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 370: 527-532, 1994
73. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukusawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994
74. Bell SM, Connoly DC, Maihle NJ, Degen JL: Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases. Mol Cell Biol 13: 5888-5897, 1993
75. Domann FE, Levy JP, Birrer MJ, Bowden GT: Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth and Differentiation 5: 9-16, 1994
76. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ: Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Oncogene 8: 877-886, 1993
77. Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb MH: Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem 268: 5097-5106, 1993
78. Shin DM, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994
79. Grandis J, Tweardy DJ: Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993
80. Sturgis E, Sacks PG, Masui H, Mendelsohn J, Schanz SP: Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Head and Neck Surgery 111: 633-643, 1994
81. Schechter AL, Hung M, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976-978, 1985
82. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB2 gene to epidermal growth factor. Nature 319: 230-234, 1986
83. Beckhardt RN, Kiyokawa N, Liu TJ, Hung M, El-Naggar A, Clayman GL: Neu oncogene in head and neck squamous cell carcinoma. Proceedings of the American Association for Cancer Research 35: 153, 1994
84. Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG: Alterations of K-ras, p53, and erbB2/neu in human lung adenocarcinomas. Journal of Thoracic Cardiovascular Surgery 107: 590-595, 1994
85. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
86. Mitra AB, Murty VVVS, Pratap M, Sodhani P, Chaganti RSK: FRBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54: 637-639, 1994
87. Lacroix H, Igleharty JD, Skinner MA, Krauss MH: Overexpression of erbB2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis. Oncogene 4: 145-151, 1989
88. Yu D, Hung MC: Expression of activated ras neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996, 1991
89. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582, 1992
90. Hou L, Shi D, Zhang HZ, Hung MC, Ling D: Oral cancer progression an c-erbB-2/neu proto-oncogene expression. Cancer Letters 65: 215-220, 1992
91. Gohji K, Nakajima M, Fabra A, Bucana CD, von Eschenbach AC, Tsuruo T, Fidler IJ: Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Japanese Journal of Cancer Research 85: 152-160, 1994
92. Matsumoto K, Horikoshi M, Rikimaru K, Enomoto S: A study of an in vitro model for invasion of oral squamous cell carcinoma. J Oral Path Med 18: 498-501, 1989
93. Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D: Induction of Mr 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 55: 963-967, 1995
94. Hurwitz A, Dushnik M, Solomon H, Ben-Chetrit A, Finci-Yeheskel Z, Milwidsky A, Mayer M, Adashi EY, Yagel S: Cytokine-mediated regulation of rat ovarian function: interleukin-1 stimulates the accumulation of a 92-kilodalton gelatinase. Endocrinology 132: 2709-2714, 1993
95. Shima I, Sasaguri Y, Kusukawa J, Nakano R, Yamana H, Fufita H, Kakegawa T, Morimatsu M: Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br J Cancer 67: 721-727, 1993